Rare Disease Trial, Recruiting NCT05954416 Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT05954416
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults or children who have a confirmed diagnosis of one of these nine rare skin conditions: Inherited epidermolysis bullosa, Ichthyosis, Ectodermal dysplasia, Incontinentia Pigmenti, Neurofibromatosis type 1, Albinism, Pemphigus, Mucous membrane pemphigoid, or Palmoplantar keratoderma.
  • People who are currently being seen, or will be seen, at one of the reference or competence centres that are part of the FIMARAD healthcare network.
  • People who are able to understand and complete a survey (for children, the survey would need to be understood by their parents or guardians).
  • People who have provided signed consent to take part in the RaDiCo-FARD study (for children, a parent or guardian must provide consent).

Who may not be able to join:

  • People for whom regular follow-up care within the FIMARAD healthcare network sites is not possible.
  • People whose diagnosis has not been officially confirmed according to the specific criteria for their condition.
  • People, or in the case of children their parents or guardians, who are not able to understand the survey.
  • People, or in the case of children their parents or guardians, who have not provided signed consent to take part in the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christine BODEMER, INSERM UMR 1163

Phone: + 33 1 44 49 46 72

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Registry
ClinicalTrials.gov
Start date
7 March 2018
Est. completion
7 March 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Individual burden score for each selected rare disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov